Home > Rheumatology > ACR 2022 > ACR 2022 Congress Round-Up > Bimekizumab: Robust 1-year results in treating psoriatic arthritis

Bimekizumab: Robust 1-year results in treating psoriatic arthritis

Presented By
Prof. Christopher Ritchlin, University of Rochester Medical Center, USA
ACR 2022
Phase 3

The 52-week phase 3 results of the dual IL-17A/F inhibitor bimekizumab indicated sustained long-term efficacy. The safety profile was in line with previous investigations.

The IL-17A and IL-17F inhibitor bimekizumab was evaluated for long-term safety and efficacy in the treatment of active psoriatic arthritis up to week 52 after demonstrating positive results at week 16 in phase 3 BE OPTIMAL trial (NCT03895203). The study included 852 patients, randomised 2:3:1 to placebo, bimekizumab 160 mg every 4 weeks, or adalimumab 40 mg every 2 weeks as the active reference group [1]. After week 16, an open-label phase started, and participants of the placebo and the bimekizumab group were treated with the study drug, while in the reference arm, medication with adalimumab remained unchanged.

The baseline features of the study cohort included a mean age of 48.7 years and 46.8% of men. Prof. Christopher Ritchlin (University of Rochester Medical Center, NY, USA) further highlighted that 58% of participants were on concomitant use of methotrexate, around half had at least 3% of psoriasis-affected body surface area, between 24.9% and 33.2% had enthesitis, and 7.9% to 13% had dactylitis. “Over 89% of patients completed week 52, with a low number of discontinuations due to treatment-emergent adverse events (TEAE) or lack of efficacy,” Prof. Ritchlin pointed out.

After 1 year, an ACR50 response was achieved by 54.5% of participants on continuous bimekizumab, 53% of those who received placebo in the first 16 weeks and then switched to bimekizumab, and 50% of participants in the reference arm. The results for Psoriasis Area and Severity Index (PASI)100 were 60.8%, 65%, and 48.5% for each arm, respectively. “We were somewhat surprised by the high PASI100 rates for adalimumab, but it is important to know that only 68 patients were in this arm, so that may have influenced this particular outcome,” Prof. Ritchlin commented. He further underlined that ACR20, ACR50, and ACR70 responses numerically increased from week 16 to week 52. After 1 year, minimal disease activity was present in 55% of participants on continuous bimekizumab, 53.7% of those receiving placebo/bimekizumab, and 52.9% of those treated with adalimumab. The radiographic progression inhibition was overall sustained in around 90% of all groups.

Comparing long-term safety between bimekizumab with the reference arm from weeks 0 to 52, the occurrence of any TEAE and serious TEAE was 79.1% versus 80.7% and 6.6% versus 7.1%, respectively. Nasopharyngitis, upper respiratory tract infections, and urinary tract infections were the most common TEAE on bimekizumab (12%, 7.1%, and 6.1%). “Oral candidiasis was observed in about 5% of the patients on bimekizumab, which is significantly higher than what we saw with adalimumab, not unexpectedly,” Prof. Ritchlin added.In his summary, he underlined that these results represent long-term efficacy and tolerability for bimekizumab in patients with psoriatic arthritis, naïve to prior biologic treatment.

  1. Ritchlin CT. Bimekizumab treatment in biologic DMARD-naïve patients with active psoriatic arthritis: 52-week efficacy and safety results from a phase 3, randomised, placebo-controlled, active reference study. L02, ACR Convergence 2022, 10–14 November, Philadelphia, USA.

Copyright ©2022 Medicom Medical Publishers

Posted on